Get the Stockscreener App
1.45
4.32%
0.06
After Hours:
1.50
0.05
+3.45%
Editas Medicine Inc stock is traded at $1.45, with a volume of 2.65M.
It is up +4.32% in the last 24 hours and up +26.09% over the past month.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
See More
Previous Close:
$1.39
Open:
$1.42
24h Volume:
2.65M
Relative Volume:
0.76
Market Cap:
$137.28M
Revenue:
$32.31M
Net Income/Loss:
$-237.09M
P/E Ratio:
-0.5035
EPS:
-2.88
Net Cash Flow:
$-219.11M
1W Performance:
-11.59%
1M Performance:
+26.09%
6M Performance:
-53.53%
1Y Performance:
-73.92%
1-Day Range:
$1.41
$1.53
1-Week Range:
$1.29
$1.6488
52-Week Range:
$0.9101
$6.69
Editas Medicine Inc Stock (EDIT) Company Profile
Name
Editas Medicine Inc
Sector
Industry
Phone
617-401-9000
Address
11 HURLEY ST., CAMBRIDGE, MA
Compare EDIT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
1.45 | 137.28M | 32.31M | -237.09M | -219.11M | -2.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-28-25 | Initiated | H.C. Wainwright | Buy |
| Dec-16-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-13-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Dec-13-24 | Downgrade | Stifel | Buy → Hold |
| Dec-13-24 | Downgrade | Truist | Buy → Hold |
| Dec-11-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-25-24 | Downgrade | BofA Securities | Buy → Underperform |
| Nov-06-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-04-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Aug-08-24 | Upgrade | BofA Securities | Neutral → Buy |
| May-09-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Oct-24-23 | Upgrade | Citigroup | Neutral → Buy |
| Oct-18-23 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-17-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-29-23 | Upgrade | Stifel | Hold → Buy |
| Jun-12-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-13-22 | Initiated | Citigroup | Neutral |
| Dec-06-22 | Resumed | Credit Suisse | Neutral |
| Nov-18-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Nov-18-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-29-22 | Initiated | BofA Securities | Neutral |
| Oct-19-21 | Initiated | SVB Leerink | Mkt Perform |
| Sep-24-21 | Initiated | Stifel | Hold |
| Sep-10-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-09-21 | Upgrade | Truist | Hold → Buy |
| Aug-05-21 | Upgrade | Evercore ISI | Underperform → Outperform |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-04-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Apr-16-21 | Initiated | Goldman | Sell |
| Mar-22-21 | Initiated | Credit Suisse | Outperform |
| Mar-01-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-26-21 | Downgrade | Truist | Buy → Hold |
| Jan-19-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-07-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-10-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-03-20 | Initiated | Robert W. Baird | Underperform |
| Jun-18-20 | Resumed | SunTrust | Buy |
| Feb-21-20 | Initiated | Wells Fargo | Equal Weight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Oct-10-18 | Initiated | Guggenheim | Neutral |
| Sep-21-18 | Initiated | Raymond James | Outperform |
| May-15-18 | Reiterated | Chardan Capital Markets | Buy |
| Feb-13-18 | Initiated | CLSA | Underperform |
| Jan-23-18 | Upgrade | SunTrust | Hold → Buy |
| Jul-14-17 | Initiated | SunTrust | Hold |
| Mar-28-17 | Initiated | Chardan Capital Markets | Buy |
| Aug-10-16 | Upgrade | Jefferies | Hold → Buy |
| Jun-02-16 | Initiated | Jefferies | Hold |
| Feb-29-16 | Initiated | JMP Securities | Mkt Outperform |
| Feb-29-16 | Initiated | JP Morgan | Neutral |
| Feb-29-16 | Initiated | Morgan Stanley | Equal-Weight |
View All
Editas Medicine Inc Stock (EDIT) Latest News
Editas Medicine (EDIT) to Release Quarterly Earnings on Wednesday - MarketBeat
Susquehanna Fundamental Investments LLC Makes New $346,000 Investment in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Zacks Research Comments on Editas Medicine FY2027 Earnings - MarketBeat
Genome Editing Market Future Business Opportunities 2025-2032 - openPR.com
HC Wainwright Estimates Editas Medicine Q1 Earnings - MarketBeat
Cantor Fitzgerald Upgrades Editas Medicine (NASDAQ:EDIT) to "Strong-Buy" - MarketBeat
Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May - GlobeNewswire
Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor ... - Bluefield Daily Telegraph
Editas Medicine Earnings Alert: Q1 2025 Results Coming May 12, Ends Quarterly Calls - Stock Titan
Editas Medicine (NASDAQ:EDIT) Stock Rating Upgraded by HC Wainwright - MarketBeat
Editas Medicine, Inc. (NASDAQ:EDIT) Receives $6.83 Consensus Target Price from Analysts - MarketBeat
Editas Medicine Inc expected to post a loss of 58 cents a shareEarnings Preview - TradingView
Renaissance Technologies LLC Purchases New Position in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
HC Wainwright & Co. Initiates Coverage of Editas Medicine (LSE:0IFK) with Buy Recommendation - Nasdaq
Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Barchart.com
Editas Medicine (EDIT) Receives Positive Coverage from H.C. Wain - GuruFocus
HC Wainwright & Co. Initiates Coverage of Editas Medicine (EDIT) with Buy Recommendation - Nasdaq
Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting | EDIT Stock N - GuruFocus
Editas Medicine to Present Five Abstracts at the 28th Annual Meeting of the American Society of Gene and Cell Therapy - Nasdaq
Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting - The Manila Times
Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in ... - Bluefield Daily Telegraph
Editas Unveils Game-Changing In Vivo Gene Editing Breakthroughs: 5 Major Studies at ASGCT 2025 - Stock Titan
Recent uptick might appease Editas Medicine, Inc. (NASDAQ:EDIT) institutional owners after losing 71% over the past year - simplywall.st
Press Release Distribution & PR Platform - ACCESS Newswire
Leerink Partnrs Forecasts Editas Medicine Q3 Earnings - MarketBeat
Cell and Gene Therapy Market Investment Trends & Emerging - openPR.com
Editas Medicine, Inc. (NASDAQ:EDIT) institutional owners may be pleased with recent gains after 71% loss over the past year - Yahoo Finance
Leerink Partnrs Weighs in on Editas Medicine Q1 Earnings - MarketBeat
New Horizons in Biomedical CRISPR Gene Editing Market Exploring - openPR.com
Leber Congenital Amaurosis Market to Show Remarkable Growth - openPR.com
Raymond James Financial Inc. Takes $303,000 Position in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Genome Editing Market Growth 2025: Trends, Consumer Demand, - openPR.com
SEC Form PRE 14A filed by Editas Medicine Inc. - Quantisnow
Why Is Editas (EDIT) Down 37.1% Since Last Earnings Report? - Yahoo Finance
Editas Medicine: Do The Risks Outweigh The Rewards? (NASDAQ:EDIT) - Seeking Alpha
Top 5 CRISPR Companies To Invest In (May 2025) - Securities.io
Editas Medicine (EDIT) Reports Q4 Loss, Misses Revenue Estimates - MSN
Editas Medicine stock hits 52-week low at $1.12 amid sharp decline - Investing.com
Editas Medicine stock hits 52-week low at $1.12 amid sharp decline By Investing.com - Investing.com South Africa
Editas Medicine Inc Stock (EDIT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):